Ironwood Pharmaceuticals, Inc. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Net Sales

106.51

47.71

122.06

85.24

41.14

90.55

91.59

Other Operating Income

0.00

Total Operating income

106.51

47.71

122.06

85.24

41.14

90.55

91.59

Raw Material Cost

0.44

0.46

0.47

0.48

0.51

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

9.14

7.89

8.43

8.36

8.07

8.91

9.42

Selling and Distribution Expenses

12.03

19.29

21.91

16.80

24.26

33.59

27.61

Other Expenses

1.24

1.35

1.36

1.45

1.89

1.60

1.99

Total Expenditure (Excl Depreciation)

33.97

41.16

44.38

40.17

51.69

58.98

57.44

Operating Profit (PBDIT) excl Other Income

72.5

6.6000000000000005

77.69999999999999

45.099999999999994

-10.5

31.6

34.2

Other Income

1.74

1.54

0.97

0.86

0.91

1.42

1.15

Operating Profit (PBDIT)

74.72

8.55

79.13

46.39

-9.16

33.47

35.81

Interest

9.14

7.89

8.43

8.36

8.07

8.91

9.42

Exceptional Items

0.04

0.25

-2.20

0.25

-18.56

-0.07

-8.52

Gross Profit (PBDT)

106.06

47.25

121.58

84.77

40.66

90.06

91.08

Depreciation

0.44

0.46

0.47

0.48

0.51

Profit Before Tax

65.17

0.46

68.02

37.82

-36.27

24.00

17.37

Tax

24.40

2.73

27.94

14.22

1.11

21.74

13.72

Provisions and contingencies

0.00

Profit After Tax

40.77

-2.28

40.08

23.60

-37.39

2.26

3.65

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

40.77

-2.28

40.08

23.60

-37.39

2.26

3.65

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

40.77

-2.28

40.08

23.60

-37.39

2.26

3.65

Equity Capital

0.00

Face Value

0.0

Reserves

-217.14

-261.83

-264.16

-308.16

-334.05

-301.33

-311.33

Earnings per share (EPS)

0.24

-0.01

0.23

0.14

-0.23

0.01

0.02

Diluted Earnings per share

0.24

-0.01

0.23

0.14

-0.23

0.01

0.02

Operating Profit Margin (Excl OI)

68.1%

13.74%

63.64%

52.88%

-25.64%

34.86%

37.29%

Gross Profit Margin

61.61%

1.92%

56.12%

44.92%

-87.0%

27.04%

19.52%

PAT Margin

38.28%

-4.77%

32.84%

27.69%

-90.87%

2.49%

3.98%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is 123.27% vs -60.93% in Dec 2025

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is 1,873.91% vs -105.74% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 942.86% vs -91.05% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is 15.19% vs -5.95% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Ironwood Pharmaceuticals, Inc. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(USD)

Change(%)

Net Sales

106.51

207.71

-101.20

-48.72%

Other Operating Income

0.00

Total Operating income

106.51

207.71

-101.20

-48.72%

Raw Material Cost

0.44

49.53

-49.09

-99.11%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

9.14

0.00

9.14

Selling and Distribution Expenses

12.03

126.67

-114.64

-90.50%

Other Expenses

1.24

3.89

-2.65

-68.12%

Total Expenditure (Excl Depreciation)

33.97

215.15

-181.18

-84.21%

Operating Profit (PBDIT) excl Other Income

72.53

-7.44

79.97

1,074.87%

Other Income

1.74

2.38

-0.64

-26.89%

Operating Profit (PBDIT)

74.72

21.09

53.63

254.29%

Interest

9.14

0.00

9.14

Exceptional Items

0.04

-0.89

0.93

104.49%

Gross Profit (PBDT)

106.06

158.17

-52.11

-32.95%

Depreciation

0.44

26.14

-25.70

-98.32%

Profit Before Tax

65.17

-5.95

71.12

1,195.29%

Tax

24.40

-3.66

28.06

766.67%

Provisions and contingencies

0.00

Profit After Tax

40.77

-2.29

43.06

1,880.35%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

40.77

-2.29

43.06

1,880.35%

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

40.77

-2.29

43.06

1,880.35%

Equity Capital

0.00

Face Value

0.00

Reserves

-217.14

1,076.81

-1,293.95

-120.17%

Earnings per share (EPS)

0.24

-0.04

0.28

700.00%

Diluted Earnings per share

0.24

-0.04

0.28

700.00%

Operating Profit Margin (Excl OI)

68.10%

-3.58%

0.00

71.68%

Gross Profit Margin

61.61%

9.72%

0.00

51.89%

PAT Margin

38.28%

-1.10%

0.00

39.38%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 10.65 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 123.27% vs -60.93% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 159.12% vs -45.13% in Mar 2025

Quarterly - Consolidate Net Profit

Consolidate Net Profit 4.08 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 1,873.91% vs -105.74% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 209.09% vs -790.48% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 7.30 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 942.86% vs -91.05% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 822.77% vs -184.17% in Mar 2025

Quarterly - Interest

Interest 0.91 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 15.19% vs -5.95% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 12.35% vs 12.50% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 68.10%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025